Emten 300 mg, 200 mg. Tablets
PDF Leaflet Revision Date: 02 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infection and Pre-Exposure Prophylaxis (PrEP) in high-risk adults.
Dosage (summary)
One tablet once daily, with or without food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding to prevent HIV transmission.
Key Drug Interactions
- Nephrotoxic medicines
- Didanosine
- Atazanavir
- Lopinavir/ritonavir
Contraindications
- Hypersensitivity to components
- Moderate to severe renal failure
- Unknown or positive HIV-1 status
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhoea
Counselling Points
- Monitor for signs of lactic acidosis
- Adhere to treatment compliance
- Regular follow-up for opportunistic infections
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Immune Reconstitution Inflammatory Syndrome
Important Disclaimer
The Emten 300 mg, 200 mg. Tablets professional information leaflet below is the property of Emcure Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
